InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,972.00
(
0.39%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.10
(
-0.37%
)
Bitcoin
57,368.23
(
1.17%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 140713

Monday, 05/21/2012 6:39:19 PM

Monday, May 21, 2012 6:39:19 PM

Post# of 252526
NVS submits NVA237 MAA in EU with brand name, Seebri Breezhaler:

http://www.sec.gov/Archives/edgar/data/1114448/000110465912038606/a12-12373_16k.htm

The FDA submission for NVA237 (as well as the FDA submission for the combination product, QVA129) is still expected in 2014, as previously announced (#msg-74789102).

The above PR has the full dataset from the successful GLOW2 phase-3 study in which NVA237 bested placebo and had similar results to the open-label active comparator, Spiriva, in moderate-to-severe COPD. Top-line results from GLOW2 were reported in Jun 2011 (#msg-64761738).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up